• PRS40 TRENDS IN ANTIBIOTIC PRESCRIBING RATES IN AMBULATORY CARE SETTINGS FOR ADULTS IN THE UNITED STATES WITH NASOPHARYNGITIS, UPPER RESPIRATORY TRACT INFECTIONS AND BRONCHITIS FROM 2006 TO 2008

    May 1, 2011, 00:00

  • PIN30 COST EFFECTIVENESS ANALYSIS OF THE COMBINATION EFAVIRENZ (EFV), TENOFOVIR (TDF) AND EMTRICITABINE (FTC) ONCE A DAY IN TREATMENT OF NAïVE ADULT PATIENTS WITH HIV INFECTION IN MEXICO

    May 1, 2011, 00:00

  • PSY35 VALIDATION OF THE LUPUS IMPACT TRACKER

    May 1, 2011, 00:00

  • PIH46 SPECIAL PRECAUTIONS TO CONSIDER WHEN PERFORMING COGNITIVE DEBRIEFING OF SENSITIVE TOPICS

    May 1, 2011, 00:00

  • PHP46 THE STATE OF HEALTH ECONOMIC EVALUATION IN SOUTH AFRICA- A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PIN44 REAL-WORLD EVALUATION OF THE ECONOMIC IMPACT OF DURATION OF DRUG THERAPY IN THE TREATMENT OF HEPATITIS C VIRUS (HCV)

    May 1, 2011, 00:00

  • CE4 USING DYNAMIC TRANSMISSION MODELS TO ESTIMATE THE COST EFFECTIVENESS OF VACCINES- FOUR DIFFERENT METHODS AND THEIR RELEVANCE FOR DECISION MAKERS

    May 1, 2011, 00:00

  • PRS30 COMPARISON OF CLINICAL AND PATIENT-REPORTED OUTCOME MEASURES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2011, 00:00

  • PMD4 PERCEPTION OF IRON DEFICIENCY IN CLINICAL PRACTICES- MULTIDISCIPLINARY FRENCH SURVEY (SUPFER SURVEY)

    May 1, 2011, 00:00

  • PIH26 MEDICATION COMPLIANCE AND ITS AFFECTING FACTORS IN CLINICAL TRIALS IN SOUTH KOREA

    May 1, 2011, 00:00

  • PND35 CREATION OF A WEB-BASED MULTIPLE SCLEROSIS PATIENT-REPORTED OUTCOMES RESEARCH PROGRAM

    May 1, 2011, 00:00

  • PSY42 EPIDEMIOLOGY AND QALITY OF LIFE OF ANEMIC PATIENTS ON DIALYSIS IN RUSSIA- PATIENT-REPORTED DATA

    May 1, 2011, 00:00

  • PMS2 ATRIAL FIBRILLATION IN OSTEOPOROTIC WOMEN TREATED WITH ALENDRONATE

    May 1, 2011, 00:00

  • PIN6 TRENDS OF HEPATITIS A INCIDENCE FROM 2005 TO 2008

    May 1, 2011, 00:00

  • PCN97 IMPACT OF GLOBAL HEALTH CARE REFORMS ON PRICING, ACCESS AND HEALTH ECONOMICS AND OUTCOMES STRATEGY

    May 1, 2011, 00:00

  • PHP91 ASSOCIATION BETWEEN QUALITY OF CARE AND SHORT TERM OUTCOMES FOR VERY OLD PATIENTS HOSPITALIZED FOR ACUTE ILLNESSES

    May 1, 2011, 00:00

  • PMH10 THE INFLUENCE OF COMORBID ANXIETY ON MEDICATION USE AND SERVICE UTILIZATION AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER- RESULTS FROM A RETROSPECTIVE CLAIMS DATABASE

    May 1, 2011, 00:00

  • PMD19 COST-EFFECTIVENESS OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION TESTING IN THE SELECTION OF FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN ONTARIO

    May 1, 2011, 00:00

  • PCV8 EVALUATION OF A SAFETY INITIATIVE AND OUTCOMES FOR PATIENTS ON STATIN-FIBRATE COMBINATION THERAPIES IN THE VETERANS AFFAIRS POPULATION

    May 1, 2011, 00:00

  • PMD36 FAILURE OF INTERNATIONAL ORGANIZATION FOR STANDARDIZATION GUIDELINES TO REPORT CLINICALLY RELEVANT INFORMATION ABOUT POINT-OF-CARE INR DEVICE PERFORMANCE

    May 1, 2011, 00:00

  • PRS44 THE CHARIOT STUDY- NOVEL DATA COLLECTION, VIEWING AND DYNAMIC REPORTING MECHANISM

    May 1, 2011, 00:00

  • PMS8 THE BUDGET IMPACT OF LOWER GPA ADHERENCE IN PATIENTS WITH CHRONIC NON-STEROIDAL AND COX-2 INHIBITOR USE

    May 1, 2011, 00:00

  • PSY80 PRIORITIZATION AND WEIGHTING OF PATIENT-RELEVANT ENDPOINTS (PRES) AS PART OF THE IQWIGS EFFICIENCY FRONTIER METHOD IN GERMANY

    May 1, 2011, 00:00

  • PCN134 HUMANISTIC CONSEQUENCES OF PREVENTABLE BLADDER TUMOR RECURRENCES IN NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

    May 1, 2011, 00:00

  • PMH5 PSYCHIATRIC ADVERSE EFFECTS RELATED TO PRESCRIPTION OF METHYLPHENIDATE IN TAIWAN

    May 1, 2011, 00:00

  • PMH31 TRAJECTORY ANALYSIS OF HEALTH CARE COSTS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH HIGH DOSES OF DULOXETINE

    May 1, 2011, 00:00

  • PRS23 NON-ADHERENCE IN ISONIAZID TREATED PATIENTS AS MEASURED BY THE TEMPTATION TO SKIP THERAPY (TEST) SCALE

    May 1, 2011, 00:00

  • PSY2 THE ASSOCIATION BETWEEN THERAPY WITH ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND HEMOGLOBIN LEVEL

    May 1, 2011, 00:00

  • PND30 QUALITY OF LIFE AMONG PATIENTS SUFFERING FROM MIGRAINE- HEALTH UTILITY BY FREQUENCY OF HEADACHE DAYS

    May 1, 2011, 00:00

  • PHP18 OPTIMAL HEALTH POLICY AND THE LINK BETWEEN OUTPUT MARKETS AND DEVELOPMENT

    May 1, 2011, 00:00

  • PCN126 OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC)- THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE

    May 1, 2011, 00:00

  • PCN69 AN ECONOMIC EVALUATION OF DASATINIB FOR THE TREATMENT OF IMATINIB RESISTANT PATIENTS WITH ADVANCED PHASE CHRONIC MYELOGENOUS LEUKAEMIA

    May 1, 2011, 00:00

  • PHP114 OPTIMIZING THE ORGANIZATION; MIGRATING HEALTH SERVICES RESEARCH OPERATIONS INTO THE COLLABORATIVE SCIENCE CENTER OF EXCELLENCE

    May 1, 2011, 00:00

  • PCN120 WHO CHOSE PRIMARY ANDROGEN DEPRIVATION THERAPY OVER RADICAL PROSTATECTOMY- A RETROSPECTIVE STUDY AMONG VETERANS WITH LOCALIZED PROSTATE CANCER

    May 1, 2011, 00:00

  • PGI21 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MILD-TO-MODERATE ULCERATIVE COLITIS BEFORE AND AFTER 8 WEEKS' TREATMENT WITH MULTI-MATRIX MESALAMINE- COMPARISON WITH 2009 GENERAL POPULATION NORMS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCV73 CONSTRUCT VALIDITY OF HEALTH UTILITIES INDEX (HUI) JAPANESE VERSION- CROSS-SECTIONAL STUDY FOR STROKE IN JAPAN

    May 1, 2011, 00:00

  • PND60 TESTING A COMPUTERIZED METHOD OF ASSESSING MOVEMENT ACCURACY

    May 1, 2011, 00:00

  • PIH27 DIFFERENCES IN PATIENT SATISFACTION WITH PRIMARY CARE AND SPECIALTY CARE

    May 1, 2011, 00:00

  • PCN28 COST SAVINGS WITH FERRIC CARBOXYMALTOSE THROUGH ITS IMPACT ON ERYTHROPOÏESIS-STIMULATING AGENTS AND BLOOD TRANSFUSION IN CHEMOTHERAPY-INDUCED ANEMIA OF BREAST AND GASTROINTESTINAL CANCER- FRENCH HEALTH CARE PAYER PERSPECTIVE

    May 1, 2011, 00:00

  • PDB25 COST OF ALL-CAUSE AND CARDIOVASCULAR DISEASE-RELATED HOSPITALIZATION IN PATIENTS WITH TYPE-2 DIABETES TREATED WITH EXENATIDE BID, SULFONYLUREAS, OR INSULIN- A RETROSPECTIVE ANALYSIS OF THE LIFELINK DATABASE

    May 1, 2011, 00:00

  • PHP27 CANADIAN PUBLIC DRUG PROGRAM SPENDING ON SENIORS, 2002 TO 2008

    May 1, 2011, 00:00

  • PRS15 ECONOMIC EVALUATION OF FLUTICASONE FUROATE COMPARED WITH MOMETASONA FUROATE FOR THE PRIMARY TREATMENT OF ALLERGIC RHINITIS PATIENTS

    May 1, 2011, 00:00

  • PRS22 COPD MAINTENANCE MEDICATION ADHERENCE- INFLUENCE ON HOSPITALIZATION AND SPENDING IN A MEDICARE POPULATION

    May 1, 2011, 00:00

  • PRM1 MEASURING COMORBIDITY- AN UPDATED CRITICAL REVIEW OF AVAILABLE METHODS

    May 1, 2011, 00:00

  • PSY50 PRESCRIPTION MONITORING PROGRAMS' UTILIZATION

    May 1, 2011, 00:00

  • PCN130 RECORD-LINKAGE FOR PHARMACOEPIDEMIOLOGIC STUDIES IN CANCER PATIENTS

    May 1, 2011, 00:00

  • PND24 QUALITY OF LIFE USING TREATMENTS FOR PARKINSON'S DISEASE- AN ECONOMIC COMPARISON BETWEEN ROPINIROLE AND LEVODOPA/CARBIDOPA

    May 1, 2011, 00:00

  • PCN41 FINANCIAL BURDEN AMONG PATIENTS WITH MAJOR CANCERS- FINDINGS FROM THE UNITED STATES MEDICAL EXPENDITURE PANEL SURVEY, 1996-2007

    May 1, 2011, 00:00

  • PHP112 DEFINITIONAL CRITERIA FOR CHRONIC FATIGUE SYNDROME- A CRITICAL REVIEW

    May 1, 2011, 00:00

  • PCV88 PATTERNS OF STATIN PRESCRIPTION AMONG PRIVATELY INSURED COMMERCIAL AND MEDICARE PATIENTS

    May 1, 2011, 00:00

  • PIH37 DUAL VETERAN HEALTH ADMINISTRATION AND MEDICARE USE AND AMBULATORY CARE SENSITIVE HOSPITALIZATIONS

    May 1, 2011, 00:00

  • PSY81 PERCEPTIONS ABOUT 'RAPID' WARFARIN REVERSAL WITH FRESH FROZEN PLASMA TO REDUCE THE INR- A NOVEL SURVEY METHODOLOGY

    May 1, 2011, 00:00

  • PGI11 THE ECONOMIC AND QUALITY OF LIFE BURDEN OF ILLNESS IN CHRONIC CONSTIPATION (CC) AND IRRITABLE BOWEL SYNDROME (IBS)- A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PMS3 RISK FACTORS FOR NON-INITIATION OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARD) BY PATIENTS WITH NEWLY DIAGNOSED RHEUMATOID ARTHRITIS (RA)

    May 1, 2011, 00:00

  • PMS58 BURDEN OF RHEUMATOID ARTHRITIS DISEASE FLARES

    May 1, 2011, 00:00

  • PSU16 LAPAROSCOPIC SUPRACERVICAL HYSTERECTOMY VERSUS LAPAROSCOPIC-ASSISTED VAGINAL HYSTERECTOMY- POST-SURGICAL OUTCOMES AND COSTS

    May 1, 2011, 00:00

  • PIH16 COST-EFFECTIVENESS OF DESVENLAFAXINE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS IN BREAST CANCER PATIENTS IN MEXICO

    May 1, 2011, 00:00

  • PSS30 BURDEN OF INFANTILE HEMANGIOMA- DEVELOPMENT OF A QUESTIONNAIRE

    May 1, 2011, 00:00

  • PRS18 THE COST-EFFECTIVENESS OF ROFLUMILAST IN THE MANAGEMENT OF SEVERE COPD IN THE UK SETTING

    May 1, 2011, 00:00

  • PCN114 DEVELOPING A FAMILIAL CANCER RISK ASSESSMENT TOOL FOR USE IN UNDERSERVED COMMUNITIES

    May 1, 2011, 00:00

  • PSY13 THE COST OF OBESITY AND ITS MAJOR COMORBIDITIES- ANALYSIS FROM A COMMERCIAL CLAIMS DATABASE

    May 1, 2011, 00:00

  • PCN4 BODY MASS INDEX AND STAGE OF DIAGNOSIS OF OVARIAN CANCER- A SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2011, 00:00

  • PND16 CHARACTERIZING DIRECT COSTS ASSOCIATED WITH HEMOPHILIA A- A RESOURCE-BASED COST ANALYSIS

    May 1, 2011, 00:00

  • PMD8 POSITRON EMISSION TOMOGRAPHY SCREENING FOR LUNG CANCER- A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PCN116 TRANSFERABILITY OF NICE RECOMMENDATIONS FOR PHARMACEUTICAL THERAPIES IN ONCOLOGY TO CENTRAL-EASTERN EUROPEAN COUNTRIES

    May 1, 2011, 00:00

  • PRM27 SF-12 AND EQ-5D UTILITY SCORING STRATEGY- LESSONS FROM APPLYING 40 SCORINGS TO 3 LARGE DATA SETS

    May 1, 2011, 00:00

  • PMS42 CONTENT VALIDITY AND HEALTH CARE SYSTEMS- A CASE-STUDY

    May 1, 2011, 00:00

  • PMH79 PSYCHOTROPIC POLYPHARMACY IN CHILDREN AND ADOLESCENTS WITH ATTENTION – DEFICIT / HYPERACTIVITY DISORDER

    May 1, 2011, 00:00

  • PIN16 COST COMPARISON OF LINEZOLID VERSUS VANCOMYCIN FOR TREATMENT OF NOSOCOMIAL PNEUMONIA AND COMPLICATED SKIN AND SOFT TISSUE INFECTION CAUSED BY MRSA IN QUEBEC

    May 1, 2011, 00:00

  • PRS36 HOSPITALIZATIONS, MEDICAL MANAGEMENT AND SWITCH THERAPY PATTERNS IN THE COPD MEDICARE POPULATION

    May 1, 2011, 00:00

  • PSS3 PERSISTENCE WITH STATINS AND THE RISK OF AGE RELATED MACULAR DEGENERATION IN A LARGE HEALTH ORGANIZATION IN ISRAEL

    May 1, 2011, 00:00

  • PHP104 CURRENT USES OF AND PERCEPTIONS ABOUT FDAMA SECTION 114

    May 1, 2011, 00:00

  • PHP17 PRESCRIPTION DRUG MONITORING PROGRAMS- THE PATIENT PERSPECTIVE

    May 1, 2011, 00:00

  • PMD9 ESTIMATION OF QUALITY-ADJUSTED LIFE EXPECTANCY AND LOSS OF QUALITY-ADJUSTED LIFE EXPECTANCY IN PATIENTS UNDER PROLONGED MECHANICAL VENTILATION- A POPULATION-BASED STUDY DURING 1998-2007 IN TAIWAN

    May 1, 2011, 00:00

  • PGI6 THE ECONOMIC BURDEN OF ADVANCED LIVER DISEASE AMONG PATIENTS WITH HEPATITIS C VIRUS- A STATE MEDICAID PERSPECTIVE

    May 1, 2011, 00:00

  • PDB26 ECONOMIC EVALUATION OF GLIMEPIRIDE AND GLIMEPIRIDE/METFORMIN FOR TYPE-2 DIABETES MELLITUS IN MEXICO

    May 1, 2011, 00:00

  • PDB70 BASELINE CHARACTERISTICS AND ANTIDIABETIC EXPOSURE IN PATIENTS WITH TYPE-2 DIABETES TREATED WITH LIRAGLUTIDE

    May 1, 2011, 00:00

  • PRM12 DOES DIFFERENTIAL DISCOUNTING ENHANCE DECISION MAKING?

    May 1, 2011, 00:00

  • PND12 LOWER DAILY AVERAGE CONSUMPTION AND GREATER PRESCRIPTION COST SAVINGS OF ARMODAFINIL COMPARED WITH MODAFINIL- A 12-MONTH RETROSPECTIVE DATABASE ANALYSIS

    May 1, 2011, 00:00

  • PIN50 CARE ORGANIZATION AND AMBULATORY CARE SENSITIVE HOSPITALIZATIONS FOR BACTERIAL PNEUMONIA

    May 1, 2011, 00:00

  • PMS29 COST-UTILITY ANALYSIS OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, LIMITED FASCIECTOMY, AND PERCUTANEOUS NEEDLE FASCIOTOMY IN DUPUYTREN'S CONTRACTURE

    May 1, 2011, 00:00

  • PCN108 CLINICAL EFFICACY AND ONCOLOGY REIMBURSEMENT RECOMMENDATIONS IN CANADA BY THE INTERIM JOINT ONCOLOGY DRUG REVIEW (IJODR)

    May 1, 2011, 00:00

  • PIN33 COST-UTILITY ANALYSIS OF RALTEGRAVIR IN HIV-INFECTED TREATMENT NAïVE PATIENTS IN SWEDEN

    May 1, 2011, 00:00

  • PSY64 GE CENTRICITY® ELECTRONIC MEDICAL RECORDS STUDY- COMORBIDITIES AND BIOLOGIC EXPERIENCE AMONG PATIENTS RECEIVING GOLIMUMAB

    May 1, 2011, 00:00

  • PCV53 COST-EFFECTIVENESS ANALYSIS COMPARING IVABRADINE WITH ISOSORBIDE MONONITRATE, AMLODIPINE, DILTIAZEM AND VERAPAMIL, IN THE TREATMENT OF STABLE ANGINA PECTORIS

    May 1, 2011, 00:00

  • PHP24 NUMBER AND TYPE OF DRUGS USED BY SENIORS ON PUBLIC DRUG PROGRAMS IN CANADA, 2002 TO 2008

    May 1, 2011, 00:00

  • PSU20 IS THERE INDICATION BIAS OF RETROSPECTIVE OBSERVATIONAL STUDY?

    May 1, 2011, 00:00

  • PCN20 EXERCISE LOWERS ESTROGEN AND PROGESTERONE LEVELS IN PREMENOPAUSAL WOMEN AT HIGH RISK OF BREAST CANCER

    May 1, 2011, 00:00

  • PMS14 DIRECT HEALTHCARE COSTS ASSOCIATED WITH OSTEOARTHRITIS

    May 1, 2011, 00:00

  • PMH58 NEW DISEASE MANAGEMENT PROGRAM FOR OPIOID DEPENDENT PATIENTS DECREASES DRUG USE AND INCREASES 12 STEP MEETING ATTENDANCE- ONE YEAR RESULTS OF A RANDOMIZED CLINICAL TRIAL

    May 1, 2011, 00:00

  • PHP5 INCENTIVE-BASED INTERVENTIONS – REWARDING PATIENTS FOR GOOD BEHAVIOUR

    May 1, 2011, 00:00

  • CO3 PROJECT LIBRA- A NEW ANALYTIC TOOL FOR COMPARATIVE EFFECTIVENESS ANALYSES OF MULTIPAYER CLAIMS DATABASES

    May 1, 2011, 00:00

  • PCV77 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HYPERTENSION IN KOREA

    May 1, 2011, 00:00

  • PIH45 MULTILEVEL ANALYSIS TO MEASURE HOSPITAL VARIATION- THE CASE OF CESAREAN DELIVERY

    May 1, 2011, 00:00

  • PIH25 IMPACT OF PATIENT BEHAVIORS AND ATTITUDES ON TERIPARATIDE ADHERENCE IN A MEDICARE PART D POPULATION

    May 1, 2011, 00:00

  • PND7 PREVALENCE OF DRUG-TREATED MULTIPLE SCLEROSIS WITHIN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM- COMPARATIVE ANALYSIS WITH PUBLISHED PREVALENCE RATES

    May 1, 2011, 00:00

  • EV1 DEVELOPMENT OF A GUIDANCE FOR INCLUDING PATIENT-REPORTED OUTCOMES (PROS) IN POST-APPROVAL CLINICAL TRIALS OF ONCOLOGY DRUGS FOR COMPARATIVE EFFECTIVENESS RESEARCH (CER)

    May 1, 2011, 00:00

  • PND50 UNDERSTANDING HEALTH RELATED QUALITY OF LIFE CHANGES AND ISSUES RELATED TO DISEASE MODIFYING DRUGS AMONG MULTIPLE SCLEROSIS PATIENTS- A QUALITATIVE STUDY

    May 1, 2011, 00:00

  • MC4 LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION- AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA

    May 1, 2011, 00:00

  • PUK16 COST-EFFECTIVENESS OF VALGANCICLOVIR 200 DAYS PROPHYLAXIS VERSUS 100 DAYS PROPHYLAXIS IN KIDNEY TRANSPLANT PATIENTS AT HIGH-RISK FOR DEVELOPING CYTOMEGALOVIRUS DISEASE

    May 1, 2011, 00:00

  • PSY10 COST ANALYSIS OF ANEMIA TREATMENT WITH ERYTHROPOIESES-STIMULATING AGENTS (ESAS) IN CANCER PATIENTS RECEIVING CHEMOTHERAPY- A MULTICOUNTRY APPROACH

    May 1, 2011, 00:00

  • PCV78 HEALTH RELATED QUALITY OF LIFE IN HYPERTENSIVE PATIENTS VISITING PUBLIC HOSPITALS OF QUETTA, PAKISTAN

    May 1, 2011, 00:00

  • DS3 AVAILABILITY OF LABORATORY RESULTS DATA IN A CLAIMS DATABASE IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMD24 GLYCOSYLATED HEMOGLOBIN OR FASTING GLUCOSE TESTING FOR SCREENING DIABETES IN COLOMBIA- A COST-EFFECTIVENESS ANALYSIS

    May 1, 2011, 00:00

  • PIH29 THE ROLE OF GENERATIONAL INFLUENCE TOWARDS COMPLEMENTARY AND ALTERNATIVE MEDICINE

    May 1, 2011, 00:00

  • PMD30 IMPACT OF ACCESS TO A USUAL SOURCE OF CARE ON COMPLIANCE TO BREAST AND CERVICAL CANCER SCREENING

    May 1, 2011, 00:00

  • PSU8 PATTERNS OF ACUTE CLOPIDOGREL USE AND INPATIENT COSTS IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING

    May 1, 2011, 00:00

  • PDB36 AN ECONOMIC MODEL OF THE EFFECTS OF QUICK RELEASE BROMOCRIPTINE MESYLATE VERSUS ALTERNATIVE ORAL ANTIDIABETIC DRUGS ON HOSPITALIZATIONS AND COSTS

    May 1, 2011, 00:00

  • PMD2 A META-ANALYSIS OF BIOMARKERS AND DIAGNOSTIC IMAGING IN ALZHEIMER'S DISEASE

    May 1, 2011, 00:00

  • PCN35 DOSING PATTERN AND COST COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA IN CHRONIC KIDNEY DISEASE AND CHEMOTHERAPY-INDUCED ANEMIA INPATIENTS

    May 1, 2011, 00:00

  • PUK12 COST-EFFECTIVENESS OF TOLTERODINE AS TREATMENT FOR OVERACTIVE BLADDER (OAB) IN ADULT MEXICAN PATIENTS

    May 1, 2011, 00:00

  • PIN11 EVALUATION OF COSTS AND INCOME OF AN EXTENDED TREATMENT OF CLINICAL MASTITIS CAUSED BY GRAM-POSITIVE PATHOGENS IN DAIRY COWS IN THE UNITED STATES- THE CASE OF PIRLIMYCIN

    May 1, 2011, 00:00

  • PMS28 COST-EFFECTIVNESS ANALYSIS OF NSAIDS FOR SYMTOMATIC TREATMENT OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS

    May 1, 2011, 00:00

  • PMH38 ECONOMIC IMPLICATIONS OF THE EFFECT OF LURASIDONE VERSUS OTHER SELECTED ATYPICAL ANTIPSYCHOTICS ON CARDIOMETABOLIC PARAMETERS IN PATIENTS WITH SCHIZOPHRENIA

    May 1, 2011, 00:00

  • PSU5 LONG-TERM CLINICAL SAFETY OF LASIK AND SURFACE ABLATION IN SOUTH KOREA THROUGH LINKAGE OF RETROSPECTIVE COHORT AND NATIONWIDE CLAIMS DATABASE

    May 1, 2011, 00:00

  • PSY43 HEALTH-RELATED QUALITY OF LIFE IN UKRAINE PATIENTS WITH HEREDITARY COAGULOPATHIES

    May 1, 2011, 00:00

  • PCV95 USING COMPUTERIZED PHYSICIAN ORDER ENTRY OF ANTI-HYPERTENSIVE MEDICATIONS TO CONNECT INDICATIONS WITH PRESCRIBING AND IMPROVE PROBLEM LIST DOCUMENTATION

    May 1, 2011, 00:00

  • PUK7 ECONOMIC EVALUATION OF CINACALCET VERSUS STANDARD TREATMENT IN PATIENTS WITH SECONDARY HYPERPARATHYROIDISM IN MEXICO

    May 1, 2011, 00:00

  • PDB6 LONG-TERM EFFECTIVENESS OF MANAGING DIABETES WITH THE CHRONIC CARE MODEL- SIMULATIONS PERFORMED USING ARCHES

    May 1, 2011, 00:00

  • PIH35 PHARMACISTS' ATTITUDE AND PREPAREDNESS REGARDING THE ISSUE OF ESCALATING PHARMACEUTICAL DEMAND DUE TO THE AGING BABY BOOMERS

    May 1, 2011, 00:00

  • PGI13 PERCEIVED VALUE ASSESSMENT OF ENTECAVIR VERSUS NO TREATMENT IN CHRONIC HEPATITIS B

    May 1, 2011, 00:00

  • PDB7 DIET THERAPIES IN PATIENTS WITH TYPE-2 DIABETES- A MIXED-TREATMENT COMPARISON OF RANDOMIZED CONTROL TRIALS

    May 1, 2011, 00:00

  • PCN6 BREAST, PROSTATE AND COLORECTAL CANCER SCREENING BEHAVIOR AND INCIDENCE OF LATE STAGE CANCER DIAGNOSIS IN ELDERLY WEST VIRGINIANS

    May 1, 2011, 00:00

  • PCV42 A DECISION MODELING APPROACH TO EVALUATE THE COST-EFFECTIVENESS OF PRASUGREL VERSUS CLOPIDOGREL IN PATIENTS WITH PLANNED PERCUTANEOUS CORONARY INTERVENTION

    May 1, 2011, 00:00

  • PCN133 ESTIMATING THE EPIDEMIOLOGY OF LATE-STAGE CANCERS – A MATHEMATICAL APPROACH

    May 1, 2011, 00:00

  • CO2 REAL-WORLD COST-EFFECTIVENESS ANALYSIS OF CANCER DRUGS- COMPARATIVE EFFECTIVENESS RESEARCH USING RETROSPECTIVE CANADIAN REGISTRY DATA BEFORE AND AFTER DRUG APPROVAL

    May 1, 2011, 00:00

  • PCN40 HEALTH CARE UTILIZATION AND COSTS OF RESECTED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN AN INCIDENT COHORT OF PATIENTS IN THE UNITED KINGDOM

    May 1, 2011, 00:00

  • PRM24 EXPLORING THE INTERRELATIONSHIP BETWEEN UNINTENTIONAL AND INTENTIONAL NONADHERENCE AMONG 24,071 ADULTS WITH CHRONIC DISEASE

    May 1, 2011, 00:00

  • PMH16 CHARACTERISTICS OF PATIENTS IN COMMUNITY BEHAVIORAL HEALTH ORGANIZATIONS RECEIVING TWO INJECTABLE FORMS OF ATYPICAL ANTIPSYCHOTIC MEDICATIONS AS COMPARED WITH OTHER ANTIPSYCHOTICS

    May 1, 2011, 00:00

  • PCV11 PNEUMONIA AFTER ACUTE ISCHEMIC STROKE- PREVALENCE, ASSOCIATED FACTORS AND OUTCOMES

    May 1, 2011, 00:00

  • PSS4 SYSTEMATIC REVIEW OF THE EPIDEMIOLOGIC LITERATURE ON ATOPIC DERMATITIS IN CHILDREN

    May 1, 2011, 00:00

  • PGI20 IBS-C PATIENT SYMPTOM REPORTS- ANALYSIS OF EXPLORATORY OPEN-ENDED QUESTIONS

    May 1, 2011, 00:00

  • PCN39 COSTS AT THE END OF LIFE FOR PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

    May 1, 2011, 00:00

  • PHP61 WIDER CONSULTATION IN HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS- BETTER UNDERSTANDING OR A LOBBYING OPPORTUNITY?

    May 1, 2011, 00:00

  • PIH36 DRUG PRESCRIBING BEHAVIOR FOR THE TREATMENT OF HEAVY MENSTRUAL BLEEDING

    May 1, 2011, 00:00

  • PRS4 LITERATURE REVIEW OF RISK FACTORS FOR MORTALITY OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2011, 00:00

  • PSS18 DISEASE SEVERITY EVALUATION AMONG DERMATOLOGICAL OUT-PATIENTS- A COMPARISON BETWEEN THE ASSESSMENTS OF PATIENTS AND PHYSICIANS

    May 1, 2011, 00:00

  • PDB71 CHARACTERISTICS OF EARLY ADOPTERS OF EXPENSIVE MEDICATIONS

    May 1, 2011, 00:00

  • PDB22 INSULIN GLARGINE PLUS OHAS VERSUS BIPHASIC INSULIN IN TYPE-2 DIABETES – A COST COMPARISON

    May 1, 2011, 00:00

  • PHP6 EXPLORE THE USE OF DRUGS IN MEDICAL INSURANCE BILLING IN CHINA

    May 1, 2011, 00:00

  • PDB65 ECONOMIC BURDEN OF CUSHING'S DISEASE- A POPULATION ANALYSIS OF DIRECT MEDICAL COSTS AND UTILIZATION

    May 1, 2011, 00:00

  • PSY41 HEALTH-RELATED QUALITY OF LIFE IN KAZAKHSTAN PATIENTS WITH HEREDITARY COAGULOPATHIES

    May 1, 2011, 00:00

  • PMD40 METHODOLOGICAL CONSIDERATIONS IN MODELING THE ECONOMIC VALUE OF DIAGNOSTIC ACCURACY

    May 1, 2011, 00:00

  • PCN89 HTA AGENCIES' PREFERENCES REGARDING QUALITY OF LIFE MEASURES FOR PROSTATE CANCER CLINICAL TRIALS

    May 1, 2011, 00:00

  • PHP49 UTILIZATION AND COST OF THE HEALTH PLAN - EFFECTS OF SPOUSAL BEREAVEMENT

    May 1, 2011, 00:00

  • PDB41 TREATMENT GAPS AMONG GROWTH HORMONE USERS IN A NATIONAL MANAGED CARE POPULATION IN THE UNITED STATES

    May 1, 2011, 00:00

  • PSS22 SYSTEMATIC REVIEW OF THE QUALITY OF LIFE LITERATURE IN CHILDREN WITH ATOPIC DERMATITIS

    May 1, 2011, 00:00

  • PDB50 MEDICATION BELIEFS AMONG LOW-INCOME AFRICAN AMERICANS AND CAUCASIANS WITH DIABETES

    May 1, 2011, 00:00

  • PDB1 TREATMENT PATTERNS AND OUTCOMES AMONG OLDER EXENATIDE BID USERS COMPARED TO INSULIN GLARGINE USERS

    May 1, 2011, 00:00

  • PMH65 EFFECT OF PRESCRIPTION MONITORING PROGRAMS (PMP'S) ON OPIOID OVERDOSE ADMISSION

    May 1, 2011, 00:00

  • PIH23 A SYSTEMATIC LITERATURE REVIEW OF BEHAVIORAL RISK FACTORS ASSOCIATED WITH INITIAL MEDICATION ADHERENCE

    May 1, 2011, 00:00

  • PSY11 BURDEN OF ILLNESS IN FIBROMYALGIA SYNDROME- THE PATIENTS' PERSPECTIVES

    May 1, 2011, 00:00

  • PCN5 USING HEALTH CLAIMS DATA TO STUDY PATTERNS OF CERVICAL CANCER SCREENING AND DIAGNOSIS IN A STATE MEDICAID FEE-FOR-SERVICE POPULATION (FUNDING- AHRQ – P20-HS15930)

    May 1, 2011, 00:00

  • PCN59 COST EFFECTIVENESS ANALYSIS OF LAPATINIB/CAPECITABINE (LC) VERSUS TRASTUZUMAB/CAPECITABINE (TC) IN PATIENTS WITH METASTATIC BREAST CANCER ERBB2+ AFTER PROGRESSION TO THE FIRST SCHEME OF TRASTUZUMAB

    May 1, 2011, 00:00

  • PCV1 DOES ROUTE OF ADMINISTRATION FOR ESTROGEN HORMONE THERAPY IMPACT RISK OF VENOUS THROMBOEMBOLISM- ESTRADIOL TRANSDERMAL SYSTEM VERSUS ORAL ESTROGEN-ONLY HORMONE THERAPY

    May 1, 2011, 00:00

  • PIN4 EFFICACY AND SAFETY OF THE COMBINATION EFAVIRENZ (EFV), TENOFOVIR (TDF) AND EMTRICITABINE (FTC) ONCE A DAY IN TREATMENT OF NAïVE ADULT PATIENTS WITH HIV-1 INFECTION- A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PHP67 UNDERSTANDING THE VIETNAMESE PRICING AND REIMBURSEMENT ENVIRONMENT THROUGH A COMPARISON WITH THAT OF CHINA

    May 1, 2011, 00:00

  • PCV76 PATIENT SYMPTOM EXPERIENCES FOLLOWING A MYOCARDIAL INFARCTION

    May 1, 2011, 00:00

  • PHP31 REVIEW OF HIGHLY SPECIALIZED MEDICAL SERVICES IN KAZKAHSTAN WITHIN AN INTRODUCTIN OF UNIFIED NATIONAL HEALTH SYSTEM

    May 1, 2011, 00:00

  • PCN117 ASSOCIATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) WITH ISS STAGE AND ECOG STATUS IN MULTIPLE MYELOMA

    May 1, 2011, 00:00

  • PCV72 THE RISK OF STROKE AND PREVENTATIVE STEPS AMONG PATIENTS DIAGNOSED WITH ATRIAL FIBRILLATION IN THE UNITED STATES

    May 1, 2011, 00:00

  • PSY61 CHARACTERISTICS OF GOLIMUMAB UTILIZATION AND COSTS IN A SPECIALTY PHARMACY PROVIDER (SPP) SETTING

    May 1, 2011, 00:00

  • PCN70 USING PHARMACOECONOMIC MODELING TO DETERMINE A VALUE-BASED PRICE OF NEW CANCER DRUGS IN MALAYSIA

    May 1, 2011, 00:00

  • PMD10 SCREENING TREATMENT AND CONTROL OF HYPERTENSION IN DIABETIC PATIENTS USING OUTPATIENT VISIT DATA

    May 1, 2011, 00:00

  • PUK20 EARLY DETECTION, SCREENING, AND MANAGEMENT OF CHRONIC KIDNEY DISEASE AMONG ACTIVELY EMPLOYED – AN INTEGRATED POPULATION HEALTH MANAGEMENT APPROACH

    May 1, 2011, 00:00

  • PCN99 ITALIAN MONITORING REGISTRY OF BEVACIZUMAB IN THE TREATMENT OF METASTATIC COLON RECTAL CARCINOMA

    May 1, 2011, 00:00

  • PCN15 CORRELATES FOR HUMAN PAPILLOMA VIRUS VACCINATION UPTAKE IN A LARGE HEALTH ORGANIZATION IN ISRAEL

    May 1, 2011, 00:00

  • PCV107 IDENTIFYING EFFICIENT ACUTE CLINICAL PATHWAYS FOR CHEST PAIN- USING RISK ADJUSTED COST-EFFECTIVENESS (RAC-E) TO COMPARE HOSPITALS USING LINKED, ROUTINELY COLLECTED DATA

    May 1, 2011, 00:00

  • PSS20 MEDIATION MODELING AND MEASUREMENT CHARACTERISTICS OF THE ITCH SEVERITY SCORE FROM A PHASE 2B TRIAL OF ORAL CP-690-550 IN PATIENTS WITH MODERATE TO-SEVERE PLAQUE PSORIASIS

    May 1, 2011, 00:00

  • PMD20 COST-EFFECTIVENESS ANALYSIS OF A NEW INDEX FOR PROSTATE CANCER DETECTION

    May 1, 2011, 00:00

  • PMH27 IDENTIFICATION AND COST OF TREATMENT-RESISTANT DEPRESSION USING A CLAIMS SIGNATURE

    May 1, 2011, 00:00

  • PCN73 UTILISATION OF ANTINEOPLASTIC AGENTS IN SLOVAK REPUBLIC

    May 1, 2011, 00:00

  • PGI7 THE ECONOMIC BURDEN OF REFRACTORY GERD- A RESTROSPECTIVE CLAIMS DATABASE STUDY

    May 1, 2011, 00:00

  • PMH50 A TIME-TRADE-OFF STUDY OF HEALTH-RELATED QUALITY OF LIFE ADVANTAGE OF LONG-ACTING INJECTABLE ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA

    May 1, 2011, 00:00

  • PHP38 UTILIZATION, PRICE AND SPENDING OF ANTI-TUMOR NECROSIS FACTOR BIOLOGICS IN THE UNITED STATES MEDICAID PROGRAM

    May 1, 2011, 00:00

  • PMD23 COST-EFFECTIVENESS OF SPECIFIC USE OF THE LANCET BD QUIKHEEL® IN SCREENING PROGRAM OF NEONATAL CONGENITAL HYPOTHYROIDISM IN MEXICO

    May 1, 2011, 00:00

  • PND65 TRANSLATABILITY ASSESSMENT OF THE POST-MIGRAINE QUESTIONNAIRE

    May 1, 2011, 00:00

  • PCN60 COST-EFFECTIVENESS OF PEGFILGRASTIM VERSUS FILGRASTIM AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMA AND MYELOMA

    May 1, 2011, 00:00

  • PCV20 PERSISTENCE WITH STATINS AND PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS- A POPULATION-BASED COHORT STUDY

    May 1, 2011, 00:00

  • PIH31 SELF MEDICATION- ASSESSMENT OF STATUS, PRACTICES AND PERCEPTION

    May 1, 2011, 00:00

  • PCV19 A BAYESIAN MULTIPLE TREATMENT COMPARISON OF PULMONARY ARTERIAL HYPERTENSION DRUG CLASSES BASED ON THE RISK OF MORTALITY REPORTED IN CLINICAL TRIALS

    May 1, 2011, 00:00

  • PND18 BURDEN OF WALKING AND MOBILITY PROBLEMS IN MS- ANALYSIS OF CAREGIVER AND INDIRECT COSTS

    May 1, 2011, 00:00

  • PDB72 TWO-WAY INTERACTION EFFECT ANALYSIS OF DIABETES COMPLICATIONS ON HEALTH COSTS AND HEALTH OUTCOMES IN MEDICARE INPATIENTS

    May 1, 2011, 00:00

  • EE3 PERFORMANCE OF DIFFERENT COMORBIDITY MEASURES IN PREDICTING HEALTH CARE EXPENDITURE IN PATIENTS WITH DEMENTIA

    May 1, 2011, 00:00

  • PHP3 FEDERAL ENFORCEMENT ACTIONS AGAINST FRAUD AND ABUSE BY PHARMACEUTICAL MANUFACTURERS- 1996-2010

    May 1, 2011, 00:00

  • PCN92 PSYCHOMETRIC COMPARISION OF THE EQ-5D-3L TO THE EQ-5D-5L IN CANCER PATIENTS IN KOREA

    May 1, 2011, 00:00

  • PRM22 STAGES OF NON-PERSISTENCE- A NOVEL WAY OF FRAMING LONGITUDINAL PERSISTENCE TO CHRONIC MEDICATIONS

    May 1, 2011, 00:00

  • PDB12 USE OF ANTIDEPRESSANTS AND THE RISK OF DIABETES MELLITUS- A NESTED CASE-CONTROL STUDY

    May 1, 2011, 00:00

  • PRS33 EFFECTS OF EDUCATIONAL INTERVENTIONS FOR SELF-MANAGEMENT OF ASTHMA IN CHILDREN AND ADOLESCENTS- AN UPDATED SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS

    May 1, 2011, 00:00

  • PSS23 COMPARING HEALTH-RISK BURDEN AND TOTAL HEALTHCARE COSTS OF PSORIASIS WITH TOP FIVE CHRONIC CONDITIONS

    May 1, 2011, 00:00

  • PMH85 A SCHIZOPHRENIA OR BIPOLAR TYPE I DISORDER REGISTRY- LESSONS LEARNED FROM CONDUCTING A REGISTRY STUDY WITH SAFETY NET PROVIDERS

    May 1, 2011, 00:00

  • PCV62 PERSISTENCE AND COMPLIANCE IN HYPERTENSION TREATMENT WITH OLMESARTAN MEDOXOMIL – ANALYSIS OF REAL-LIFE PRESCRIPTION DATA

    May 1, 2011, 00:00

  • PIN2 HEALTH OUTCOMES OF CLINICALLY RELEVANT PATIENT POPULATIONS TREATED WITH DAPTOMYCIN FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) SKIN INFECTIONS

    May 1, 2011, 00:00

  • PHP89 THE IMPLEMENTATION OF PUBLIC HEALTH GUIDANCE- PREFERENCE FOR CLINICAL OVER BEHAVIOURAL INTERVENTIONS

    May 1, 2011, 00:00

  • PCN25 BUDGET-IMPACT OF ERIBULIN FOR THIRD-LINE TREATMENT OF METASTATIC BREAST CANCER IN A UNITED STATES MANAGED CARE SETTING

    May 1, 2011, 00:00

  • PDB43 TREATMENT COMPLIANCE TO DIABETES CARE- A CROSS-SECTIONAL STUDY FROM PAKISTAN

    May 1, 2011, 00:00

  • PHP65 HEALTH OUTCOMES AND ECONOMICS RESEARCH FOR CELLULAR THERAPIES AND REGENERATIVE MEDICINES- LESSONS FROM A HEALTH TECHNOLOGY ASSESSMENT AND REIMBURSEMENT ANALYSIS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PHP43 THE INFLUENCE OF PATIENT ACCESS SCHEMES ON APPRAISAL DECISIONS BY NICE IN THE UNITED KINGDOM

    May 1, 2011, 00:00

  • PRM34 EVALUATING THE SCREENING ABILITY OF PATIENT-REPORTED OUTCOME INSTRUMENTS

    May 1, 2011, 00:00

  • PND6 THE IMPACT OF SPECIALTY CARE PROGRAMS ON RELAPSES OF MULTIPLE SCLEROSIS USING ADMINISTRATIVE DATA

    May 1, 2011, 00:00

  • PRS26 RELIABILITY AND VALIDITY OF THE EXACT-RESPIRATORY SYMPTOMS (E-RS) SCORE TO QUANTIFY THE SEVERITY OF RESPIRATORY SYMPTOMS OF COPD

    May 1, 2011, 00:00

  • PMH57 ASSOCIATION BETWEEN WORK PRODUCTIVITY AND SEVERITY OF DEPRESSION AMONG FULL-TIME EMPLOYEES AS MEASURED BY THE WPAI HPQ

    May 1, 2011, 00:00

  • PMS7 THE IMPACT OF RHEUMATOID ARTHRITIS ON CARDIOVASCULAR MORBIDITY IN A HIGH RISK MEDICAID POPULATION

    May 1, 2011, 00:00

  • PSS8 SYSTEMATIC REVIEW OF THE ECONOMIC LITERATURE ON ATOPIC DERMATITIS IN CHILDREN

    May 1, 2011, 00:00

  • PMH19 THE BUDGET IMPACT ANALYSIS OF NALTREXONE IN THE TREATMENT OF ALCOHOL-DEPENDENT PATIENTS IN POLAND

    May 1, 2011, 00:00

  • PCV39 CHARACTERIZATION OF COSTS ASSOCIATED WITH STROKE REHABILITATION- A REVIEW OF THE LITERATURE

    May 1, 2011, 00:00

  • PMH3 RISK OF HIP FRACTURES IN ELDERLY MEDICARE BENEFICIARIES USING ATYPICAL OR TYPICAL ANTIPSYCHOTICS- A PROPENSITY SCORE ANALYSIS

    May 1, 2011, 00:00

  • PMH32 COMPARISON OF REAL-WORLD HEALTH CARE COSTS AFTER THE INITIATION OF SECOND-LINE DULOXETINE OR GENERIC SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN PATIENTS WITH MAJOR DEPRESSIIVE DISORDER

    May 1, 2011, 00:00

  • PMH47 THE RELATIONSHIP BETWEEN BUPRENORPHINE-MEDICATION ASSISTED TREATMENT ADHERENCE AND HEALTH CARE COSTS AND SERVICE UTILIZATION- AN ANALYSIS OF AETNA'S OPIOID DEPENDENT MEMBERS

    May 1, 2011, 00:00

  • PCN57 ECONOMICS OF A MULTI-GENE ASSAY TO PREDICT RECURRENCE OF EARLY STAGE BREAST CANCER- EXPERIENCE OF A LARGE UNITED STATES INSURANCE PROGRAM

    May 1, 2011, 00:00

  • PCN91 ARTHRALGIA AND PATIENT-REPORTED OUTCOMES IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER TAKING AROMATASE INHIBITORS- LONGITUDINAL ANALYSES

    May 1, 2011, 00:00

  • PGI1 INCIDENCE OF ANEMIA AND NEUTROPENIA FOLLOWING HCV TREATMENT INITIATION AND RELATED DRUG TREATMENT COSTS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PHP29 EVALUATING THE PERFORMANCE OF AN INNOVATIVE PUBLIC HEALTH INSURANCE- THE CASE OF A DECENTRALIZED PROVINCE IN ARGENTINA

    May 1, 2011, 00:00

  • PSS21 GAP ANALYSIS FOR PATIENT-REPORTED OUTCOMES MEASURES FOR ALOPECIA

    May 1, 2011, 00:00

  • PIH13 THE COST-EFFECTIVENESS OF THE LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS, MIRENA®) FOR THE TREATMENT OF HEAVY MENSTRUAL BLEEDING IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCV104 REAL-WORLD SIDE EFFECT DATA ON CHOLESTEROL MEDICATIONS – OUTPUTS FROM AN ONLINE PATIENT COMMUNITY

    May 1, 2011, 00:00

  • PRS14 A COST-EFFECTIVENESS ANALYSIS ON THE USE OF INDACATEROL FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN MEXICO

    May 1, 2011, 00:00

  • PHP88 INFLUENCE OF HOSPITAL CHOICES OF DRUGS ON THE PHARMACEUTICAL CONSUMPTION IN THE COMMUNITY

    May 1, 2011, 00:00

  • PHP83 HTA DECISION DRIVERS FOR ACCEPTANCE OF HIGH ICER SUBMISSIONS AND REJECTION OF LOW ICER SUBMISSIONS

    May 1, 2011, 00:00

  • PCV86 INSURANCE STATUS AND THE USE OF ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) AND ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS AMONG POST-MYOCARDIAL INFARCTION (MI) PATIENTS

    May 1, 2011, 00:00

  • PHP56 DEMONSTRATING CLINICAL-EFFECTIVENESS USING INDIRECT AND MIXED TREATMENT COMPARISON ANALYSIS- A REVIEW OF MANUFACTURERS' SINGLE TECHNOLOGY APPRAISAL (STA) SUBMISSIONS TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)

    May 1, 2011, 00:00

  • PMH49 CAN THE ILLNESS PERCEPTION QUESTIONNAIRE BE USED TO ASSESS MENTAL HEALTH PRACTITIONERS' PERSPECTIVES ON PATIENTS WITH SCHIZOPHRENIA?

    May 1, 2011, 00:00

  • PDB18 FACTORS ASSOCIATED WITH ROUTINE PROPER MONITORING OF DIABETES CARE AMONG THE NON-INSTITUTIONALIZED POPULATION IN THE UNITED STATES- A RETROSPECTIVE ANALYSIS OF THE 2007 MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

    May 1, 2011, 00:00

  • PCN8 REAL LIFE OUTCOMES IN 1ST LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)- A PILOT STUDY IN FRANCE AND GERMANY ANALYSING BEVACIZUMAB-BASED VERSUS NON-BEVACIZUMAB-BASED TREATMENTS

    May 1, 2011, 00:00

  • PHP45 TRENDS OF HEALTH CARE UTILIZATION AMONG LOYAL PATIENTS IN A MEDICAL CENTER UNDER TAIWAN'S UNIVERSAL HEALTH INSURANCE PROGRAM

    May 1, 2011, 00:00

  • PCN2 SAFETY AND TREATMENT PATTERNS OF ANGIOGENESIS INHIBITORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN THE UNITED KINGDOM- PRELIMINARY RESULTS OF AN ONGOING CHARTS REVIEW STUDY

    May 1, 2011, 00:00

  • PCV99 MEDICAL RESOURCE UTILIZATION AND COSTS FOLLOWING HOSPITALIZATION OF PATIENTS WITH CHRONIC HEART FAILURE IN THE UNITED STATES

    May 1, 2011, 00:00

  • DU3 IMPACT OF THE FDA'S ANTIPSYCHOTIC BLACK BOX WARNING ON PSYCHOTROPIC DRUG PRESCRIBING IN ELDERLY PATIENTS WITH DEMENTIA IN OUTPATIENT AND OFFICE-BASED SETTINGS

    May 1, 2011, 00:00

  • PIH44 MULTIDOMAIN LONGITUDINAL MODELING- APPLICATION TO THE INTERNATIONAL INDEX OF ERECTILE FUNCTION

    May 1, 2011, 00:00

  • PSY60 ECONOMIC CONSEQUENCES OF UNDER-UTILIZATION WITH TUMOR NECROSIS FACTOR INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS

    May 1, 2011, 00:00

  • PRS19 COST-UTILITY OF VARENICLINE VERSUS INTERVENTIONS AVAILABLE FOR QUITTING SMOKING IN PANAMA USING THE BENESCO MODEL

    May 1, 2011, 00:00

  • PMD1 IMPACT OF VAGUS NERVE STIMULATION (VNS) THERAPY ON CLINICAL OUTCOMES AND COSTS IN MEDICAID PATIENTS WITH DRUG-RESISTANT EPILEPSY

    May 1, 2011, 00:00

  • DU4 THE LONG TERM UTILIZATION OF STIMULANTS IN CHILDREN AND ADOLESCENTS- A MEDICAID STUDY

    May 1, 2011, 00:00

  • MD1 USING COST-EFFECTIVENESS INFORMATION TO ALLOCATE MEDICARE RESOURCES – HOW MUCH MORE HEALTH FOR THE MONEY?

    May 1, 2011, 00:00

  • PCV112 EXTENSION OF META-ANALYSIS IN COMPARING OF FIMASARTAN WITH LOSARTAN IN BLOOD PRESSURE LOWERING EFFECT

    May 1, 2011, 00:00

  • PMS35 COST UTILITY ANALISYS OF CHONDROITIN SULPHATE(CS) IN THE TREATMENT OF OSTEOARTHRITIS (OA) OF THE KNEE IN MEXICAN PATIENTS

    May 1, 2011, 00:00

  • PMH37 THE COST-EFFECTIVENESS OF GUANFACINE EXTENDED RELEASE (GXR) VERSUS ATOMOXETINE (ATX) FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS

    May 1, 2011, 00:00

  • PCN17 MULTI-COHORT MODEL OF PREVALENCE ESTIMATION OF ADVANCED MALIGNANT MELANOMA IN THE UNITED STATES- RESULTS COMPARED TO SEER DATA

    May 1, 2011, 00:00

  • DU1 COMPARATIVE SAFETY OF STIMULANT AND ATOMOXETINE ASSOCIATED WITH THE RISK OF SUBSTANCE USE DISORDER AMONG ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

    May 1, 2011, 00:00

  • PDB48 DO WE KNOW WHAT ARE THEY TRADING OFF? – A FEASIBILITY STUDY TO MEASURE QUALITY OF LIFE IN TAIWANESE TYPE-2 DIABETES OUTPATIENTS BY TIME-TRADE-OFF METHOD

    May 1, 2011, 00:00

  • PMS73 PATIENT-CENTRIC OBSERVATIONAL STUDY ON CORRELATES OF INTENT TO PERSIST WITH TREATMENT- A REGRESSION MODEL IN OSTEOPOROSIS

    May 1, 2011, 00:00

  • PHP113 IQWIG AND HIQA, WHAT ARE THEY GOOD FOR? THE EVOLUTION OF THE HTA AGENCY- TIME FROM CREATION TO FIRST ASSESSMENT AND IMPACTFUL APPRAISAL

    May 1, 2011, 00:00

  • PDB13 USE OF ANTIDEPRESSANTS AND THE RISK OF DIABETES MELLITUS- A RETROSPECTIVE COHORT STUDY

    May 1, 2011, 00:00

  • PMH54 CAREGIVER BURDEN IN SCHIZOPHRENIA - A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PMH46 THE EFFECT OF ANTIPSYCHOTIC ADHERENCE ON ADHERENCE TO DIABETES, HYPERLIPIDEMIA, AND HYPERTENSION MEDICATIONS AND ASSOCIATED HEALTH SERVICE UTILIZATION

    May 1, 2011, 00:00

  • PCV24 EVALUATION OF THE CLINICAL FACTORS AND PREVENTIVE MEDICATIONS ASSOCIATED WITH THE LENGTH OF HOSPITAL STAY AMONG ISCHEMIC STROKE PATIENTS

    May 1, 2011, 00:00

  • PND26 MEASURING THE IMPACT OF NATALIZUMAB THERAPY ON HEALTH CARE UTILIZATION IN A COMMERCIALY MANAGED MULTIPLE SCLEROSIS POPULATION

    May 1, 2011, 00:00

  • PDB10 ASSESSING THE ABILITY OF PATIENT REPORTED MEASURES TO DISCRIMINATE PROXIES FOR TREATMENT RESPONSE

    May 1, 2011, 00:00

  • PDB21 A COST COMPARISON OF A BASAL BOLUS REGIMEN (INSULIN GLARGINE AND INSULIN GLULISINE) WITH A CONVENTIONAL PRE-MIXED INSULIN REGIMEN IN TYPE-2 DIABETES PATIENTS – THE GINGER STUDY

    May 1, 2011, 00:00

  • DS2 A VALIDATION STUDY OF ALGORITHMS FOR IDENTIFYING METASTATIC BREAST, LUNG, OR COLORECTAL CANCER IN ADMINISTRATIVE CLAIMS DATA

    May 1, 2011, 00:00

  • PHP74 CLINICAL TRIAL LEARNING CURVES AFFECT OUTCOMES MEASUREMENT, PATIENT SAFETY AND TRIAL SUCCESS- CONTRIBUTING FACTORS AND A POTENTIAL SOLUTION IN CLINICAL TRIAL SIMULATION

    May 1, 2011, 00:00

  • PMS1 DO BISPHOSPHONATES CAUSE ATYPICAL FEMUR FRACTURES?

    May 1, 2011, 00:00

  • PMH52 PATIENT AND PHYSICIAN PREFERENCES AND SATISFACTION WITH ORAL AND LONG-ACTING INJECTABLE LONG-TERM ANTIPSYCHOTIC TREATMENT FOR PSHYCHOTIC DISORDERS

    May 1, 2011, 00:00

  • PIH40 RETROSPECTIVE DATABASE ANALYSIS OF TREATMENT PATTERNS AND HEALTH CARE COSTS AMONG WOMEN WITH IDIOPATHIC HEAVY MENSTRUAL BLEEDING

    May 1, 2011, 00:00

  • PSU23 ASSESSING THE OUTCOME OF SHOULDER SURGERY- DEVELOPMENT, VALIDATION AND RESPONSIVENESS OF THE PATIENT-REPORTED OXFORD SHOULDER SCORE (OSS)

    May 1, 2011, 00:00

  • PHP26 ANALYSIS OF THE SIX PROTECTED MEDICATION CLASSES BASED ON PLAN TYPE AND LOW INCOME SUBSIDY STATUS

    May 1, 2011, 00:00

  • PHP13 THE IMPACT OF A QUALITY IMPROVEMENT INITIATIVE ON INAPPROPRIATE MEDICATION USE IN THE OUTPATIENT ELDERLY

    May 1, 2011, 00:00

  • PMH63 RISK-BENEFIT ANALYSIS OF DEPRESSION TREATMENT FOR CHILDREN AND YOUNG ADULTS

    May 1, 2011, 00:00

  • PGI26 PATIENT CHARACTERISTICS ASSOCIATED WITH USE OF ENTERAL VERSUS PARENTERAL ACID SUPPRESSIVE AGENTS IN INTENSIVE CARE UNIT PATIENTS

    May 1, 2011, 00:00

  • PIH24 RACIAL DISPARITIES IN MEDICATION UNDERUSE- THE ROLE OF PATIENT SATISFACTION WITH CARE

    May 1, 2011, 00:00

  • PRM15 ADHERENCE IS ADHERENCE IS ADHERENCE- THE CONSISTENCY OF MORISKY ADHERENCE SCORES ACROSS THE COSTLIEST CHRONIC CONDITIONS

    May 1, 2011, 00:00

  • EE1 SYSTEMATIC REVIEW OF GUIDELINES FOR HEALTH ECONOMIC EVALUATIONS

    May 1, 2011, 00:00

  • PIH21 COST-UTILITY ANALYSIS OF DIENOGEST VERSUS GNRH ANALOGUE IN THE TREATMENT OF ENDOMETRIOSIS-ASSOCIATED PELVIC PAIN IN SLOVAKIA

    May 1, 2011, 00:00

  • PND3 THE NATURE AND PREVALENCE OF COMORBID ILLNESS AMONG INDIVIDUALS WITH MULTIPLE SCLEROSIS

    May 1, 2011, 00:00

  • PMS53 USE OF TNF-INHIBITORS IN THE UNITED STATES- UTILIZATION PATTERNS AND DOSE-ESCALATION FROM A REPRESENTATIVE UNITED STATES RA POPULATION

    May 1, 2011, 00:00

  • PRS20 A COST-UTILITY ANALYSIS ON THE USE OF INDACATEROL FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN MEXICO

    May 1, 2011, 00:00

  • PIN37 HOW MANY IMMUNIZATION DOSES WERE MISSED IN PEDIATRICES YOUNGER THAN 2 YEARS?

    May 1, 2011, 00:00

  • PSU7 A DISCRETE EVENT SIMULATION MODEL TO ESTIMATE THE LONG TERM OUTCOMES OF BARIATRIC SURGERY IN MEXICO

    May 1, 2011, 00:00

  • PMH55 THE BURDEN OF DIAGNOSED DEPRESSION AND SLEEP DIFFICULTIES ON QUALITY OF LIFE, WORK PRODUCTIVITY, AND RESOURCE USE

    May 1, 2011, 00:00

  • PND44 HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS WITH DYSPORT IN CERVICAL DYSTONIA

    May 1, 2011, 00:00

  • PMS30 COST-UTILITY ANALYSIS OF DENOSUMAB VERSUS STANDARD CARE IN THE TREATMENT OF POST-MENOPAUSAL OSTEOPOROSIS IN PORTUGAL

    May 1, 2011, 00:00

  • Guide for Authors

    May 1, 2011, 00:00

  • PHP28 COMPLIANCE WITH TREATMENT GUIDELINE RECOMMENDATIONS- USE OF OVER-THE-COUNTER MEDICATIONS IN PATIENTS RECEIVING BISPHOSPHONATES, ANTIEPILEPTICS, OR CHRONIC OPIOIDS

    May 1, 2011, 00:00

  • PMD5 OUTCOME STUDY OF DRUG ELUTING STENT (DES) VERSUS BARE METAL STENT (BMS) IN HONG KONG- A 6-MONTH PILOT STUDY

    May 1, 2011, 00:00

  • PSY45 CHARACTERISTICS OF CAREGIVERS AND THEIR EXPERIENCE ASSOCIATED WITH CONGENITAL HEMOPHILIA OF INHIBITOR PATIENTS

    May 1, 2011, 00:00

  • PND38 THE HIDDEN TOLL OF CAREGIVER BURDEN IN MULTIPLE SCLEROSIS

    May 1, 2011, 00:00

  • PRS27 THE DEVELOPMENT OF A PATIENT-REPORTED OUTCOME INSTRUMENT TO EVALUATE NIGHTTIME SYMPTOMS OF COPD

    May 1, 2011, 00:00

  • PDB39 A DESCRIPTIVE ANALYSIS OF TREATMENT ADHERENCE WITH GROWTH HORMONE- FINDINGS FROM A NATIONAL MANAGED CARE POPULATION IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMD12 GENDER DIFFERENCES IN TOTAL KNEE ARTHROPLASTY (TKA) POSTOPERATIVE PAIN MANAGEMENT IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMS4 THE ASSOCIATION BETWEEN TERIPARATIDE PERSISTENCE AND FRACTURE OUTCOMES IN A US CLAIMS DATABASE

    May 1, 2011, 00:00

  • PIH15 ECONOMIC EVALUATION OF ANALGESIC MANAGEMENT AFTER TOTAL ABDOMINAL HYSTERECTOMY AT THE SOCIAL SECURITY MEXICAN INSTITUTE

    May 1, 2011, 00:00

  • PCN121 ONCOLOGY MEDICATION UTILIZATION BASED ON FEDERAL DRUG ADMINISTRATION (FDA) LABELING, NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) CLINICAL PRACTICE GUIDELINE (GL) RECOMMENDATIONS, AND EVIDENCE FOR PATIENTS WITH ADVANCED NON SMALL CEL ...

    May 1, 2011, 00:00

  • PHP48 STATUS OF PHARMACIST AT COMMUNITY LEVEL- AN EXPLORATORY STUDY IN QUETTA, PAKISTAN

    May 1, 2011, 00:00

  • PMD25 THE COST-UTILITY AND VALUE OF INFORMATION OF TRANSCATHETER AORTIC VALVE IMPLANTATION COMPARED TO STANDARD MANAGEMENT AND SURGICAL AORTIC VALVE REPLACEMENT IN PATIENTS WITH SEVERE SYMPTOMATIC AORTIC VALVE STENOSIS

    May 1, 2011, 00:00

  • PHP10 THE TEMPORAL ASSOCIATION BETWEEN PRESCRIBED OPIOIDS AND THE NATIONAL DEATH RATE DUE TO OPIOID POISONING

    May 1, 2011, 00:00

  • PHP15 ISSUES ASSOCIATED WITH BIOLOGIC AGENTS- HEALTHCARE STAKEHOLDER SURVEY

    May 1, 2011, 00:00

  • PND15 THE INCREMENTAL COST OF ALZHEIMER'S DISEASE IN THE CALIFORNIA MEDICAID PROGRAM (MEDI-CAL)

    May 1, 2011, 00:00

  • PDB23 THE IMPACT OF TREATMENT MODIFICATION ON HEALTHCARE EXPENDITURE IN PATIENTS WITH TYPE-2 DIABETES INITIATING EXENATIDE BID OR INSULIN GLARGINE

    May 1, 2011, 00:00

  • PCN96 CANCER PATIENT PREFERENCES AND WILLINGNESS TO PAY FOR PREVENTING CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN THE UNITED STATES

    May 1, 2011, 00:00

  • PIH2 LEAD DETOXIFYING EFFECT OF VITAMIN C IN TRAFFIC POLICE SUBJECTS

    May 1, 2011, 00:00

  • PND64 APPLICATION OF PREDICTIVE MODELING TO CLASSIFY FREQUENT SNORING IDENTIFIED FROM ROUTINE MEDICAL EXAMINATIONS USING THE NHANES DATABASE

    May 1, 2011, 00:00

  • PHP107 BIOMARKERS- A CHANGING PARADIGM FOR DEVELOPMENT

    May 1, 2011, 00:00

  • PHP60 ORPHAN DRUGS FACE TOUGHER SCRUTINY IN SECURING FAVORABLE PRICING AND MARKET ACCESS

    May 1, 2011, 00:00

  • PIN45 IMPACT OF GOVERNMENT SPONSORED POLIO CONTROL PROGRAM ON KNOWLEDGE, ATTITUDE AND PERCEPTION OF POLIO IN GENERAL COMMUNITY OF BAHAWALPUR, PAKISTAN

    May 1, 2011, 00:00

  • PSS11 COST-EFFECTIVENESS ANALYSIS OF FORMULARY MANAGEMENT STRATEGIES FOR FIRST-LINE AGENTS USED IN OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION

    May 1, 2011, 00:00

  • PDB64 EVALUATION OF THE BURDEN OF ILLNESS OF TYPE-2 DIABETES MELLITUS IN A MEDICARE POPULATION

    May 1, 2011, 00:00

  • PMS38 IMPACT OF MEDICARE PART D COVERAGE GAP ON MEDICATION TAKING BEHAVIOR- AN EVALUATION ACROSS DUAL AND NON-DUAL ELIGIBLE BENEFICIARIES DIAGNOSED WITH RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PCN32 COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN CHRONIC KIDNEY DISEASE AND CHEMOTHERAPY-INDUCED ANEMIA OUTPATIENTS

    May 1, 2011, 00:00

  • PRM49 TRANSLATION AND LINGUISTIC VALIDATION – METHODOLOGICAL IMPLICATIONS WHEN THE SOURCE MEASURE IS NOT ENGLISH

    May 1, 2011, 00:00

  • PMH68 FDA REGULATIONS AND ANTIDEPRESSANT UTILIZATION

    May 1, 2011, 00:00

  • PGI22 CONCORDANCE AMONG MULTIPLE HEALTH OUTCOMES MEASURES IN RESPONSIVENESS TO MULTI-MATRIX MESALAMINE MAINTENANCE TREATMENT FOR PATIENTS WITH QUIESCENT ULCERATIVE COLITIS

    May 1, 2011, 00:00

  • PMS57 ASSOCIATION OF CLINICAL REMISSION AND NORMALIZED PATIENT REPORTED OUTCOMES- A VALIDATION OF TREAT-TO-TARGET FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS USING POOLED DATA FROM 3 PHASE III GOLIMUMAB CLINICAL TRIALS

    May 1, 2011, 00:00

  • PHP32 ANALYSIS OF PHARMACISTS' INTERVENTIONS ON ELECTRONIC VERSUS TRADITIONAL PRESCRIPTIONS IN TWO COMMUNITY PHARMACIES

    May 1, 2011, 00:00

  • PCN84 PATIENTS' PREFERENCES FOR THE TREATMENT OF COLORECTAL CANCER- A DISCRETE CHOICE EXPERIMENT (DCE) SURVEY

    May 1, 2011, 00:00

  • PSY79 CONTENT VALIDITY OF THE MULTIPLE SCLEROSIS INTERNATIONAL QOL (MUSIQOL) QUESTIONNAIRE IN IRAN, EGYPT, MOROCCO, SAUDI ARABIA AND TUNISIA

    May 1, 2011, 00:00

  • PCN31 DIRECT MEDICAL COSTS OF ELDERLY PATIENTS WITH STAGE III COLON CANCER DURING FIRST-LINE VERSUS SECOND-LINE CHEMOTHERAPY

    May 1, 2011, 00:00

  • PRM35 DEVELOPMENT OF A CONCEPT LIST TO ENSURE COMPARABLE CONTENT VALIDITY BETWEEN ORIGINAL PRO QUESTIONNAIRES AND THEIR TRANSLATIONS- A REVIEW OF 15 YEARS OF LINGUISTIC VALIDATIONS

    May 1, 2011, 00:00

  • PND45 ONE YEAR OF NATALIZUMAB TREATMENT IS ASSOCIATED WITH AN IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS

    May 1, 2011, 00:00

  • PCN62 BAYESIAN MODELLING ASSESSING THE EFFECTIVENESS OF A VACCINATION STRATEGY TO PREVENT HPV-RELATED DISEASES- THE BEST STUDY

    May 1, 2011, 00:00

  • PHP95 EXPECTED CHANGES IN HEALTH CARE UTILIZATION DUE TO PATIENT PROTECTION AND AFFORDABLE CARE ACT

    May 1, 2011, 00:00

  • PMH45 MEASURES OF MEDICATION ADHERENCE IN ORAL VERSUS LONG-ACTING RISPERIDONE IN TEXAS MEDICAID PATIENTS WITH SCHIZOPHRENIA

    May 1, 2011, 00:00

  • PMH22 CLINICAL AND ECONOMIC CONSEQUENCES OF LONG-TERM USE OF BENZODIAZEPINES IN PATIENTS WITH GENERALIZED ANXIETY DISORDER

    May 1, 2011, 00:00

  • PND61 EVALUATION OF CONSISTENCY BETWEEN MULTIPLE SCLEROSIS REGISTRY PUBLICATIONS

    May 1, 2011, 00:00

  • PMH39 COST-EFFECTIVENESS OF ANTIDEPRESSANT THERAPIES IN KOREA

    May 1, 2011, 00:00

  • PSS2 DIAGNOSED AND UNDIAGNOSED DRY EYE, SYMPTOM SEVERITY, AND ASSOCIATED FACTORS AMONG MEN AND WOMEN IN THE UNITED STATES

    May 1, 2011, 00:00

  • SB4 A METHODOLOGY FOR ASSESSING TREATMENT EFFECT IN THE PRESENCE OF DISEASE SEVERITY AND COMORBIDITY IN RETROSPECTIVE OBSERVATIONAL STUDIES

    May 1, 2011, 00:00

  • PCV84 EFFECTIVENESS OF A MEDICAL EDUCATION INTERVENTION TO TREAT HYPERTENSION IN PRIMARY CARE

    May 1, 2011, 00:00

  • PRM14 VALIDATING AN ONLINE CALCULATOR FOR EVALUATING HEALTH INTERVENTION OPTIONS USING THE ANALYTIC HIERARCHY PROCESS (AHP)

    May 1, 2011, 00:00

  • PIN7 EPIDEMIOLOGY OF HIV-RELATED NEUROPATHY – A SYSTEMATIC LITERATURE REVIEW

    May 1, 2011, 00:00

  • PRS11 ESTIMATING THE ECONOMIC BURDEN OF FOOD-INDUCED ALLERGIC REACTIONS AND ANAPHYLAXIS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCV65 NEW STATIN USERS' PERSISTENCE AND ADHERENCE- BOTH ARE CRITICAL CONCEPTS IN THE COMPREHENSIVE CHARACTERIZATION OF MEDICATION EXPOSURE

    May 1, 2011, 00:00

  • PHP78 CHARACTERISTICS OF HOMELESS INDIVIDUALS USING INPATIENT AND EMERGENCY DEPARTMENT SERVICES

    May 1, 2011, 00:00

  • PUK1 INCIDENCE AND 30-DAY MORTALITY OF COMMUNITY ACQUIRED PNEUMONIA (CAP) IN THE MEDICARE FEE-FOR-SERVICE (FFS) POPULATION

    May 1, 2011, 00:00

  • PCV22 META REGRESSION ANALYSIS TO INDIRECTLY COMPARE THE SAFETY AND EFFICACY OF DALTEPARIN TO ENOXAPARIN IN PATIENTS WITH UNSTABLE CORONARY ARTERY DISEASE

    May 1, 2011, 00:00

  • PHP101 VALUE BASED PRICING- WHAT IS THE FUTURE FOR PATIENT ACCESS SCHEMES?

    May 1, 2011, 00:00

  • PCV66 ADHERENCE RATES AMONG HEALTH PLAN MEMBERS STARTING GENERIC VERSUS BRAND STATIN THERAPY

    May 1, 2011, 00:00

  • PMH2 RISK OF HOSPITALIZATION FOR PNEUMONIA ASSOCIATED WITH THE USE OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTICS IN A NATIONAL SAMPLE OF MEDICARE BENEFICIARIES

    May 1, 2011, 00:00

  • PSY1 SEVERE RENAL, HEPATIC AND GASTROINTESTINAL EVENTS ASSOCIATED WITH DEFERASIROX IN PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA

    May 1, 2011, 00:00

  • PCV2 THE RISK OF CARDIOVASCULAR EVENTS ASSOCIATED WITH DIETARY CALCIUM AND VITAMIN D SUPPLEMENTS IN PATIENTS WITH OSTEOPOROSIS

    May 1, 2011, 00:00

  • PSS9 COST-EFFECTIVENESS OF COLLAGENASE VERSUS HYDROGEL DRESSINGS FOR CHRONIC-WOUND DEBRIDEMENT IN A LONG-TERM CARE SETTING

    May 1, 2011, 00:00

  • PDB61 DECOMPOSING GENDER DIFFERENCES IN ANGIOTENSIN II CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS AMONG VETERANS WITH DIABETES

    May 1, 2011, 00:00

  • PDB59 THE COMPLEXITY OF DRUG THERAPY AND SOCIO-ECONOMIC VARIANTS IN PATIENTS WITH DIABETES

    May 1, 2011, 00:00

  • PSY12 BASELINE CHARACTERISTICS AND PRE–INDEX TOTAL HEALTH CARE AND RHEUMATOID ARTHRITIS-RELATED COSTS IN PATIENTS RECEIVING GOLIMUMAB THERAPY

    May 1, 2011, 00:00

  • PIN23 COST-EFFECTIVENESS OF ATAZANAVIR/RITONAVIR (ATV+RTV) COMPARED WITH LOPINAVIR/RITONAVIR (LPV+RTV) IN TREATMENT-NAÏVE HIV-INFECTED PATIENTS IN MEXICO- A MODEL BASED ON THE CASTLE STUDY

    May 1, 2011, 00:00

  • PCV5 PREVALENCE, INCIDENCE, AND OUTCOMES OF CRITICAL LIMB ISCHEMIA IN THE MEDICARE POPULATION IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCV34 PROPHYLAXIS USE AND 90-DAY COSTS FOR VENOUS THROMBOEMBOLISM, MAJOR AND MINOR BLEEDING EVENT ANALYSIS IN HOSPITALIZED MEDICALLY ILL PATIENTS

    May 1, 2011, 00:00

  • PHP75 USE OF ELECTRONIC MEDICAL RECORDS FROM 2001 THROUGH 2010- IMPLICATIONS FOR COMPARATIVE EFFECTIVENESS RESEARCH

    May 1, 2011, 00:00

  • PSY26 IMPACT OF HYPONATREMIA ON PATIENT OUTCOMES AND HEALTH CARE RESOURCE UTILIZATION IN HOSPITALIZED PATIENTS

    May 1, 2011, 00:00

  • PRS45 MODELING THE IMPACT OF MULTIPLE QUIT ATTEMPTS IN SMOKERS USING DISCRETE EVENT SIMULATION (DES)

    May 1, 2011, 00:00

  • PCN125 MELODY BRASIL- TREATMENT PATTERNS AND ASSOCIATED COSTS OF METASTATIC MELANOMA PATIENTS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM (SUS)

    May 1, 2011, 00:00

  • PIH3 COMPARISON OF IN VITRO FERTILIZATION TRENDS AMONG INSURED PATIENTS IN MANAGED CARE IN THE UNITED STATES; COMPARISON OF STATES WITH AND WITHOUT MANDATED COMPREHENSIVE FERTILITY COVERAGE

    May 1, 2011, 00:00

  • PCN43 STUDY ON MEDICAL EXPENDITURE AND PAYMENT PATTERNS OF INSURED PATIENTS WITH CANCER IN CHINA

    May 1, 2011, 00:00

  • PND23 ECONOMIC EVALUATION OF DEXMEDETOMIDINE FOR SEDATION IN THE INTENSIVE CARE UNIT

    May 1, 2011, 00:00

  • PSY29 A COMPARISON OF DAILY AVERAGE SUPPLY (DASUP) OF OXYCODONE AND OXYMORPHONE LONG-ACTING ORAL TABLETS

    May 1, 2011, 00:00

  • PDB58 WHAT IS THE IMPACT OF GENERIC SUBSTITUTION OF ROSIGLITAZONE ON PATIENT OUTCOMES AND TREATMENT COSTS? AN HMO EXPERIENCE

    May 1, 2011, 00:00

  • PCN136 ESTIMATING UTILITIES IN CANCER- A COMPARISON OF EQ-5D AND FACT-BASED ALGORITHMS

    May 1, 2011, 00:00

  • PCN119 VALIDATION OF A NEW MEASURE OF PATIENT EMPOWERMENT IN ONCOLOGY- FIVE HEALTH EDUCATION IMPACT QUESTIONNAIRE (HEIQ) SCALES

    May 1, 2011, 00:00

  • PSY20 ECONOMIC EVALUATION OF SEQUENTIAL ANALGESIC TREATMENT IN THE MANAGEMENT OF MODERATE ANKLE SPRAIN IN MEXICAN ADULTS

    May 1, 2011, 00:00

  • PCV7 ANALYSIS OF TREATMENT PATTERNS AND COSTS FOR VENOUS THROMBOEMBOLISM, MAJOR AND MINOR BLEEDING EVENTS IN HOSPITALIZED MEDICALLY ILL PATIENTS

    May 1, 2011, 00:00

  • PMH78 PERSISTENCE OF STIMULANT TREATMENT IN CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER

    May 1, 2011, 00:00

  • PRM47 DEVELOPMENT OF LOCALLY ADAPTABLE VALUE ARGUMENTS- HOW CAN BUCKETING OF COUNTRIES AT GLOBAL LEVEL HELP MANUFACTURERS?

    May 1, 2011, 00:00

  • PMD11 IDENTIFYING POTENTIAL DRIVERS OF COST SAVINGS WITH INSULIN ADMINISTRATION DEVICES IN TYPE-2 DIABETES IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMS34 COST-UTILITY ANALYSIS OF DENOSUMAB VERSUS RALOXIFENE FOR TREATING OSTEOPOROSIS IN POST-MENOPAUSAL WOMEN IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMS67 FREQUENCY OF SELECT ANTI-TNF ADMINISTRATION OR RE-FILL IN PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PND25 ECONOMIC TRENDS ASSOCIATED WITH NATALIZUMAB THERAPY IN A COMMERCIALY MANAGED MULTIPLE SCLEROSIS POPULATION

    May 1, 2011, 00:00

  • PDB56 IMPACT OF PHARMACIST MANAGEMENT ON PATIENTS WITH DIABETES ENROLLED IN A RURAL FREE CLINIC

    May 1, 2011, 00:00

  • QA2 CROSS-WALKING CANCER-SPECIFIC INSTRUMENTS TO THE EQ-5D AND SF-6D

    May 1, 2011, 00:00

  • PGI15 COST EFFECTIVENES OF THE PHARMACOLOGIC TREATMENT OF IRRITABLE BOWEL SYNDROME AT THE SOCIAL SECURITY MEXICAN INSTITUTE

    May 1, 2011, 00:00

  • PDB69 EXENATIDE (BID) AND LIRAGLUTIDE (QD) TREATMENT PATTERNS AMONG TYPE-2 DIABETES PATIENTS IN GERMANY

    May 1, 2011, 00:00

  • PSY51 EFFECTIVENESS OF FDA'S NEW OVER-THE-COUNTER ACETAMINOPHEN LABEL WARNING REQUIREMENTS IN IMPROVING CONSUMER RISK PERCEPTION OF LIVER DAMAGE

    May 1, 2011, 00:00

  • PGI5 COMPARISON OF HEALTH CARE UTILIZATIONS BETWEEN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE WHO SWITCHED FROM A BRANDED PROTON PUMP INHIBITOR TO A GENERIC PROTON PUMP INHIBITOR AND VICE VERSA

    May 1, 2011, 00:00

  • PMH64 COMPARISON OF THE RISPERIDONE EQUIVALENT DOSES FOR THE 9 MOST FREQUENT TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN PATIENTS DIAGNOSED WITH SCHIZOPHRENIA BASED ON PRODUCT LABELS WITH ACTUAL DOSAGES PRESCRIBED IN A LARGE NATIONAL DATABASE

    May 1, 2011, 00:00

  • CN3 THE VALUE OF RESEARCH FOR ERCC1 TESTING IN STAGE I NON-SMALL CELL LUNG CANCER

    May 1, 2011, 00:00

  • PCN19 AN EPIDEMIOLOGICAL MODEL OF BREAST CANCER AND PROGRESSION TO BONE METASTASES IN THE UNITED KINGDOM

    May 1, 2011, 00:00

  • CO4 POTENTIAL COST SAVINGS FROM COMPARATIVE EFFECTIVENESS RESEARCH- LESSONS FROM COURAGE STUDY

    May 1, 2011, 00:00

  • PMS31 TITLE- THE RELATIVE COST-EFFECTIVENESS OF THE MOST COMMON NON-SURGICAL TREATMENTS FOR NECK PAIN

    May 1, 2011, 00:00

  • PHP76 THE OUTLOOK OF LARGE SIMPLE TRIALS FOR COMPARATIVE EFFECTIVENESS RESEARCH- AN APPLICATION OF THE PRECIS FRAMEWORK

    May 1, 2011, 00:00

  • PHP111 OVER INFLATION OF THE GENETIC CONTRIBUTION TO SCHIZOPHRENIA- IMPLICATIONS FOR NOVEL THERAPEUTICS

    May 1, 2011, 00:00

  • PCN111 ANALYSIS OF HEALTH OUTCOMES IN BREAST CANCER PATIENTS USING CLUSTER ANALYSIS

    May 1, 2011, 00:00

  • PSS7 MEDICAL CARE COSTS ASSOCIATED WITH VISION LOSS IN TAIWAN

    May 1, 2011, 00:00

  • PSY39 EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN KAZAKHSTAN- PATIENT-REPORTED DATA

    May 1, 2011, 00:00

  • PCN1 CHEMOTHERAPY INDUCED NAUSEA AND VOMITING EVENT RATE AMONG PATIENTS WITH CANCER TREATED WITH HIGHLY OR MODERATELY EMETOGENIC CHEMOTHERAPY AND INITIATED ON PALONOSETRON VERSUS OTHER 5-HT3-RECEPTOR ANTAGONIST ANTI-EMETIC PROPHYLAXIS IN A ...

    May 1, 2011, 00:00

  • PCV30 A META-ANALYSIS OF RISK FACTORS TO DEVELOP CARDIOVASCULAR EVENTS AND STROKE IN SUBJECTS EXPOSED TO ENVIROMENTAL TOBACCO SMOKE

    May 1, 2011, 00:00

  • PIH7 POTENTIALLY INAPPROPRIATE MEDICATION USE AMONG OLDER ADULTS IN THE UNITED STATES IN 2007

    May 1, 2011, 00:00

  • OR1 THE ASSOCIATION BETWEEN SELF-PERCEIVED COGNITIVE DIFFICULTIES AND LEVEL OF DEPRESSION AMONG EMPLOYEES WITH CURRENT DEPRESSION

    May 1, 2011, 00:00

  • PMH9 RISK OF DEATH IN DUAL ELIGIBLE NURSING HOME RESIDENTS USING ANTIPSYCHOTIC AGENTS

    May 1, 2011, 00:00

  • PDB8 EFFECTIVENESS AND ADHERENCE WITH FIXED-DOSE COMBINATION (FDC) VERSUS COADMINISTERED DUAL THERAPY (CDT) ANTIHYPERGLYCEMIC REGIMENS- A META-ANALYSIS

    May 1, 2011, 00:00

  • PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

    May 1, 2011, 00:00

  • PHP79 ROLE OF HTA SYSTEMS IN REIMBURSEMENT AND MARKET ACCESS- COMPARISON OF TURKEY AND POLAND

    May 1, 2011, 00:00

  • PCN135 ECONOMIC CONSEQUENCES OF PREVENTABLE BLADDER TUMOR RECURRENCES IN NON-MUSCLE INVASIVE BLADDER CANCER

    May 1, 2011, 00:00

  • PHP87 IMPACT OF PRESCRIPTION MONITORING PROGRAMS ON CONTROLLED SUBSTANCE PRESCRIBING BEHAVIOR

    May 1, 2011, 00:00

  • PSY40 EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN UKRAINE- PATIENT-REPORTED DATA

    May 1, 2011, 00:00

  • PMD41 SELECTING A SECONDARY DATA SOURCE FOR A LOW-VOLUME PROCEDURE IN A SPECIALTY POPULATION- A STUDY USING INPATIENT PEDIATRIC COLONOSCOPY

    May 1, 2011, 00:00

  • CO1 COMPARATIVE EFFECTIVENESS ANALYSIS OF TNF BLOCKERS IN RHEUMATOID ARTHRITIS (RA) PATIENTS IN A REAL-WORLD SETTING

    May 1, 2011, 00:00

  • PHP68 THE 15 YEARS EXPERIENCE OF NEW DRUGS ADOPTION AND REIMBURSEMENT IN TAIWAN'S NATIONAL HEALTH INSURANCE

    May 1, 2011, 00:00

  • PMS60 PATIENT OUTCOMES ASSOCIATED WITH BIOLOGIC INFUSION SITE OF CARE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PIN34 INTRANASAL LIVE ATTENUATED (LAIV) VERSUS INJECTABLE INACTIVATED (TIV) INFLUENZA VACCINE FOR CHILDREN AND ADOLESCENTS- A CANADIAN COST EFFECTIVENESS ANALYSIS

    May 1, 2011, 00:00

  • PCN87 HOW DOES PATIENT-REPORTED OUTCOME DATA INFLUENCE THE CLINICAL DECISION MAKING OF PRACTICING ONCOLOGISTS?

    May 1, 2011, 00:00

  • PCV23 COMPARING THE EFFECTIVENESS OF ROSUVASTATIN AND ATORVASTATIN IN PREVENTING CARDIOVASCULAR OUTCOMES- ESTIMATES USING THE ARCHIMEDES MODEL

    May 1, 2011, 00:00

  • SB2 ZEROS AND NON-REPORTED HEALTH CARE AND WORKPLACE PRODUCTIVITY DATA- AN APPLICATION OF TWO-STAGE ESTIMATION TECHNIQUES MEASURING INPATIENT COSTS AND ABSENTEEISM ASSOCIATED WITH LOW BACK AND NECK PAIN

    May 1, 2011, 00:00

  • PRM43 BIOSIMILARS- DEMONSTRATING SIMILARITY THROUGH EVIDENCE

    May 1, 2011, 00:00

  • PCN76 SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES LEAD TO CONSIDERABLE HEALTH RESOURCE UTILISATION IN EUROPE- ANALYSIS OF A MULTINATIONAL OBSERVATIONAL STUDY

    May 1, 2011, 00:00

  • PMD39 MINI-HTA TRENDS FOR MEDICAL DEVICES IN THE NORDICS

    May 1, 2011, 00:00

  • PCV93 HEALTH EXPENDITURE COMPARISON OF METOPROLOL SUCCINATE VS METOPROLOL TARTARATE

    May 1, 2011, 00:00

  • PRS8 DISEASE PROGRESSION IN CYSTIC FIBROSIS — SYNTHESIS OF SURVIVAL EVIDENCE

    May 1, 2011, 00:00

  • PDB66 COSTS OF THE PHARMACEUTICAL PROGRAM TO TREAT T2DM PATIENTS FROM HIPERDIA- GOVERNMENT HEALTH CARE PROGRAM FOR DIABETES AND HYPERTENSION POPULATION UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM

    May 1, 2011, 00:00

  • PCV106 RE-HOSPITALIZATION RATES OF ACUTE CORONARY SYNDROME PATIENTS IN REAL WORLD CLINICAL PRACTICE- OBSERVATIONS FROM A NATIONAL ADMINISTRATIVE CLAIMS DATA

    May 1, 2011, 00:00

  • PMH84 PERFORMANCE OF TWO INSTRUMENTAL VARIABLES TO EXAMINE THE RISK OF DEATH IN DUAL ELIGIBLE ELDERLY NURSING HOME RESIDENTS USING ANTIPSYCHOTIC AGENTS

    May 1, 2011, 00:00

  • PCN118 PREDICTING THE FUTURE IMPACT OF EMERGING TECHNOLOGIES ON HEPATOCELLULAR CARCINOMA (HCC)- MEASURING STAKEHOLDERS PREFERENCES WITH BEST-WORST SCALING

    May 1, 2011, 00:00

  • PDB75 THE IMPACT OF HOSPITAL DAYS ON CALCULATION OF PDC FOR DIABETES MEDICATIONS

    May 1, 2011, 00:00
  • «
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138 (current)
  • 139
  • 140
  • »